Clinical Trial Update: Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial assessing 26-week AR1001 treatment for efficacy and safety in mild to moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AR1001

Snippet

Sponsor: AriBio Co., Ltd. | Conditions: Mild to Moderate Alzheimer's Disease | Phase 2 | Status: COMPLETED